A Phase 2 clinical trial involves the use of oral metronidazole to reduce Fn levels in CRC tissues, with the goal of assessing its impact on tumour cells and the surrounding microenvironment (Oncology Institute of Southern Switzerland, 2024). The gene discussed is FN1; the disease is neoplasm.